Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
about
Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin MimeticsNiacin, an old drug with a new twistNovel concepts in HDL pharmacology.Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?The therapeutic role of niacin in dyslipidemia managementEffect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Gene activation regresses atherosclerosis, promotes health, and enhances longevity.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementNiacin: another look at an underutilized lipid-lowering medication.Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.Niacin for primary and secondary prevention of cardiovascular events.Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy.Gene-activation mechanisms in the regression of atherosclerosis, elimination of diabetes type 2, and prevention of dementia.Nicotinic Acid Accelerates HDL Cholesteryl Ester Turnover in Obese Insulin-Resistant Dogs.The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotypeNovel HDL-directed pharmacotherapeutic strategies.Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism.Dyslipidemia and blood-brain barrier integrity in Alzheimer's diseaseFasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects.Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.Novel Pathways of Apolipoprotein A-I Metabolism in High-Density Lipoprotein of Different Sizes in HumansDistinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a).Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring Study.Type 1 Deiodinase Regulates ApoA-I Gene Expression and ApoA-I Synthesis Independent of Thyroid Hormone SignalingManagement of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Established and emerging approaches for the management of dyslipidaemia.Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.Dietary Niacin Supplementation Suppressed Hepatic Lipid Accumulation in Rabbits.Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.New evidence for nicotinic acid treatment to reduce atherosclerosis.Nicotinic acid: clinical considerations.Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.
P2860
Q26765137-C883080B-7D60-4F8D-9E2C-3A832F97C52EQ27002774-75BCEE6C-17D4-4F35-A5B7-FB7A0083287FQ27692691-3E252D8C-BE15-48B5-B212-30997620B397Q28086787-6BDE8A9A-6445-4559-9D45-A4347C53F740Q28304559-25F6408B-DCAB-4814-84A6-FDF1D328D9DBQ33537687-5470FA3A-80B8-4F37-AF6D-C719620DEB79Q33590777-63A50FAA-87DE-4EFB-9D68-BB99E91E0439Q33776194-CD1B3031-F33C-4147-BFC9-8BF87C62DFEFQ34020016-FDA752E3-E3DC-4DD8-A416-D223113902C7Q34181381-A18F5A10-450E-4538-AE81-294FD0284416Q34255686-5A2AB5D1-FD43-4D8D-80E9-4F6906DB3BB4Q34624990-0E8FA5F3-3265-4171-A8C2-88ADCA1522C4Q34682221-B0B28690-9D58-4D9F-9D7F-2E9EBC928556Q34805517-0391E906-41A9-4D75-9E3F-4FC7750C5A7FQ34931247-12354731-0588-4974-BF8C-15DD3ACAAE0EQ35767230-5D7627AE-386A-4329-9EA8-B4F3DF77037DQ35772231-8B54C1D7-BF37-4170-B514-15A28DCA3677Q35784769-F450DD76-8A08-4AD5-8D6B-EA069AD098A8Q35860020-511CBAD2-C3D4-412A-B13C-7AEF200B0B01Q35895434-9B681A40-D7DF-4AEE-9ECA-E52AF8E8FFF4Q35958491-D9E8CEDF-508E-4EB7-8323-6CB1938C4527Q35986336-031E8E46-3B0D-4801-92B7-7FF35439A668Q36045964-92ED3AB7-C7C3-4E74-8246-55D92F37E3F6Q36141729-A7CBCB26-F363-4F03-9916-98528C79BB95Q36403156-70666E04-2820-4B54-9213-772B953832B9Q36696683-30A776FA-F687-43BE-B99F-F88DF45B3C84Q36870960-D282F153-277C-4CBF-AD8C-0B2443AD2821Q37033898-97ECCFB4-E46C-42FD-B486-7F32F23462EEQ37167555-A98B350A-3801-40E7-B169-EE65CD1C96C0Q37254899-926BE28B-327B-4F36-B987-68BD1582911AQ37288105-307B047A-C2F3-440F-BACE-7902706B29D6Q37367666-7443C42C-55E9-41AF-929E-C093A371D3A5Q37376937-7DD2BD6A-164B-4BCD-8DFB-349F32B07866Q37382929-46662F1D-4101-47F1-A763-8D3CD6110E74Q37762262-37D2497E-C640-493F-B513-FBEF9A00BFDFQ37772510-16F22E5B-F9E6-4725-9172-18087C5C87A8Q37799365-D8131580-60F8-44C2-AD00-63A157979178Q38008035-36E3313B-75B4-4ABC-8EE0-C05F2DA38EF1Q38011204-F024AC7B-564E-4E72-9587-1E0FE82A2BCAQ38076370-079BA5C5-8CF0-4EDF-8BF1-133AE834C664
P2860
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Extended-release niacin alters ...... ApoB-containing lipoproteins.
@en
Extended-release niacin alters the metabolism of plasma apolipoprotein
@nl
type
label
Extended-release niacin alters ...... ApoB-containing lipoproteins.
@en
Extended-release niacin alters the metabolism of plasma apolipoprotein
@nl
prefLabel
Extended-release niacin alters ...... ApoB-containing lipoproteins.
@en
Extended-release niacin alters the metabolism of plasma apolipoprotein
@nl
P2093
P2860
P1476
Extended-release niacin alters ...... ApoB-containing lipoproteins.
@en
P2093
Aaron Buchsbaum
Alice H Lichtenstein
Bela F Asztalos
Ernst J Schaefer
Katalin V Horvath
Margaret R Diffenderfer
Mawuli Nyaku
Nirupa R Matthan
P Hugh R Barrett
P2860
P304
P356
10.1161/ATVBAHA.108.164541
P407
P577
2008-06-19T00:00:00Z